

# Marc Steben

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2939039/publications.pdf>

Version: 2024-02-01

96  
papers

8,621  
citations

117453

34  
h-index

43802

91  
g-index

106  
all docs

106  
docs citations

106  
times ranked

6295  
citing authors

#	ARTICLE	IF	CITATIONS
1	Attachment and Childhood Maltreatment as Moderators of Treatment Outcome in a Randomized Clinical Trial for Provoked Vestibulodynia. <i>Journal of Sexual Medicine</i> , 2022, 19, 479-495.	0.3	4
2	Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women. <i>Tumour Virus Research</i> , 2022, 13, 200236.	1.5	3
3	Ensuring a Successful Transition From Cytology to Human Papillomavirus-Based Primary Cervical Cancer Screening in Canada by Investigating the Psychosocial Correlates of Women's Intentions: Protocol for an Observational Study. <i>JMIR Research Protocols</i> , 2022, 11, e38917.	0.5	6
4	A Call to Action: Ending the Neglect of Female Genital Schistosomiasis. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2021, 43, 3-4.	0.3	3
5	Cognitive-behavioral couple therapy versus lidocaine for provoked vestibulodynia: A randomized clinical trial. <i>Journal of Consulting and Clinical Psychology</i> , 2021, 89, 316-326.	1.6	18
6	Predictors and Moderators of Provoked Vestibulodynia Treatment Outcome Following a Randomized Trial Comparing Cognitive-Behavioral Couple Therapy to Overnight Lidocaine. <i>Behavior Therapy</i> , 2021, 52, 1502-1515.	1.3	4
7	Perceived partner responsiveness is associated with sexual well-being in couples with genito-pelvic pain. <i>Journal of Family Psychology</i> , 2021, 35, 628-638.	1.0	11
8	A health economic model to estimate the costs and benefits of an mRNA vs DNA high-risk HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada. <i>Preventive Medicine Reports</i> , 2021, 23, 101448.	0.8	5
9	COVID-19 Won't Be the Last (Or Worst) Pandemic: It's Time to Build Resilience Into Our Cervical Cancer Elimination Goals. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2020, 42, 1195-1196.	0.3	9
10	Reply to Bourgeois et al., "Incompletely Reported Important Methodological Details and Inaccurate Description of the Formulation That the Control Arms Received in a Gardasil Vaccine Trial". <i>MSphere</i> , 2020, 5, .	1.3	1
11	A National Survey of Canadian Adults on HPV: Knowledge, Attitudes, and Barriers to the HPV Vaccine. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2019, 41, 1125-1133.e6.	0.3	9
12	A mixed two-dose vaccination schedule: Not enough evidence to support a policy change in Quebec. <i>Vaccine</i> , 2019, 37, 4421.	1.7	3
13	Self-Efficacy Mediates the Attachment-Pain Association in Couples with Provoked Vestibulodynia: A Prospective Study. <i>Journal of Sexual Medicine</i> , 2019, 16, 1803-1813.	0.3	6
14	Pain Trajectories and Predictors: A 7-Year Longitudinal Study of Women With Vulvodynia. <i>Journal of Sexual Medicine</i> , 2019, 16, 1606-1614.	0.3	17
15	Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. <i>Lancet</i> , The, 2019, 394, 497-509.	6.3	630
16	A Very Common Intimate Concern: "Will My Genital Warts Ever Stop Recurring?". <i>Journal of Infectious Diseases</i> , 2019, 219, 682-684.	1.9	0
17	A National Survey of Canadian Physicians on HPV: Knowledge, Barriers, and Preventive Practices. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2019, 41, 599-607.e3.	0.3	10
18	Does Self-compassion Benefit Couples Coping With Vulvodynia? Associations With Psychological, Sexual, and Relationship Adjustment. <i>Clinical Journal of Pain</i> , 2018, 34, 629-637.	0.8	30

#	ARTICLE	IF	CITATIONS
19	Daily Anxiety and Depressive Symptoms in Couples Coping With Vulvodynia: Associations With Women's Pain, Women's Sexual Function, and Both Partners' Sexual Distress. <i>Journal of Pain</i> , 2018, 19, 552-561.	0.7	47
20	The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada. <i>Journal of Medical Virology</i> , 2018, 90, 592-598.	2.5	12
21	A Review of the Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: 10 Years of Clinical Experience in Canada. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2018, 40, 1635-1645.	0.3	33
22	Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age. <i>Obstetrics and Gynecology</i> , 2018, 132, 261-270.	1.2	25
23	A Dyadic Perspective on Childhood Maltreatment for Women With Provoked Vestibulodynia and Their Partners: Associations With Pain and Sexual and Psychosocial Functioning. <i>Journal of Sex Research</i> , 2017, 54, 308-318.	1.6	26
24	No. 207-Genital Herpes: Gynaecological Aspects. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2017, 39, e105-e111.	0.3	4
25	No. 208-Guidelines for the Management of Herpes Simplex Virus in Pregnancy. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2017, 39, e199-e205.	0.3	15
26	Recurrence of Human Papillomavirus External Genital Wart Infection Among High-Risk Adults in Montréal, Canada. <i>Sexually Transmitted Diseases</i> , 2017, 44, 700-706.	0.8	12
27	Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2016, 2, 61-69.	4.5	30
28	Are Primary and Secondary Provoked Vestibulodynia Two Different Entities? A Comparison of Pain, Psychosocial, and Sexual Characteristics. <i>Journal of Sexual Medicine</i> , 2015, 12, 1463-1473.	0.3	11
29	Associations of Anogenital Low-Risk Human Papillomavirus Infection With Cancer and Acquisition of HIV. <i>Sexually Transmitted Diseases</i> , 2015, 42, 541-544.	0.8	13
30	A Prospective 2-Year Examination of Cognitive and Behavioral Correlates of Provoked Vestibulodynia Outcomes. <i>Clinical Journal of Pain</i> , 2015, 31, 333-341.	0.8	39
31	Partner Behavioral Responses to Pain Mediate the Relationship Between Partner Pain Cognitions and Pain Outcomes in Women With Provoked Vestibulodynia. <i>Journal of Pain</i> , 2015, 16, 549-557.	0.7	20
32	Attachment, Sexual Assertiveness, and Sexual Outcomes in Women with Provoked Vestibulodynia and Their Partners: A Mediation Model. <i>Archives of Sexual Behavior</i> , 2015, 44, 1561-1572.	1.2	67
33	Barriers to Implementation of Rapid and Point-of-Care Tests for Human Immunodeficiency Virus Infection. <i>Point of Care</i> , 2015, 14, 81-87.	0.5	41
34	Genital warts. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2014, 28, 1063-1073.	1.4	47
35	To Say or not to Say: Dyadic Ambivalence over Emotional Expression and Its Associations with Pain, Sexuality, and Distress in Couples Coping with Provoked Vestibulodynia. <i>Journal of Sexual Medicine</i> , 2014, 11, 1271-1282.	0.3	35
36	A comparison of cognitive-behavioral couple therapy and lidocaine in the treatment of provoked vestibulodynia: study protocol for a randomized clinical trial. <i>Trials</i> , 2014, 15, 506.	0.7	26

#	ARTICLE	IF	CITATIONS
37	Genital herpes. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2014, 28, 1098-1110.	1.4	68
38	Psychosexual aspects of vulvovaginal pain. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2014, 28, 991-999.	1.4	57
39	Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1997-2008.	1.1	137
40	Cost-effectiveness evaluation of gender-based vaccination programs against sexually transmitted infections. Discrete and Continuous Dynamical Systems - Series B, 2014, 19, 447-466.	0.5	5
41	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, I1-I31.	1.7	261
42	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, H1-H31.	1.7	272
43	Provoked Vestibulodynia: Mediators of the Associations Between Partner Responses, Pain, and Sexual Satisfaction. Archives of Sexual Behavior, 2013, 42, 129-141.	1.2	58
44	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, F1-F31.	1.7	40
45	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, G1-G31.	1.7	33
46	Temporal Trends in Genital Warts Among Individuals Covered by the Public Prescription Drug Insurance Plan in the Province of Quebec, Canada, From 1998 to 2007. Journal of Lower Genital Tract Disease, 2013, 17, 147-153.	0.9	8
47	Do Romantic Partners' Responses to Entry Dyspareunia Affect Women's Experience of Pain? The Roles of Catastrophizing and Self-Efficacy. Journal of Sexual Medicine, 2013, 10, 2274-2284.	0.3	53
48	Genital Warts. Journal of Lower Genital Tract Disease, 2012, 16, 409-415.	0.9	17
49	Upgrading Public Health Programs for Human Papillomavirus Prevention and Control is Possible in Low- and Middle-income Countries. Vaccine, 2012, 30, F183-F191.	1.7	25
50	Genital Herpes in Canada: Deciphering the Hidden Epidemic. Canadian Journal of Infectious Diseases and Medical Microbiology, 2012, 23, e6-e9.	0.7	6
51	Epidemiological Impact of a Genital Herpes Type 2 Vaccine for Young Females. PLoS ONE, 2012, 7, e46027.	1.1	11
52	Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. , 2011, 2011, .		21
53	Adenocarcinoma <i>in situ</i> and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. International Journal of Cancer, 2011, 128, 1344-1353.	2.3	28
54	Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. International Journal of Cancer, 2011, 129, 2632-2642.	2.3	47

#	ARTICLE	IF	CITATIONS
55	Incident Cervical HPV Infections in Young Women: Transition Probabilities for CIN and Infection Clearance. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 287-296.	1.1	98
56	The humoral response to Gardasil over four years as defined by Total IgG and competitive Luminex immunoassay. <i>Hum Vaccin</i> , 2011, 7, 230-238.	2.4	97
57	Prevention of and Screening for Herpes Simplex Infection: A Survey of Quebec Physicians. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2010, 32, 126-131.	0.3	2
58	Woman and Partner-Perceived Partner Responses Predict Pain and Sexual Satisfaction in Provoked Vestibulodynia (PVD) Couples. <i>Journal of Sexual Medicine</i> , 2010, 7, 3715-3724.	0.3	84
59	Incidence, Duration, and Reappearance of Type-Specific Cervical Human Papillomavirus Infections in Young Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1585-1594.	1.1	73
60	Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2010, 341, c3493-c3493.	2.4	323
61	Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women. <i>Journal of the National Cancer Institute</i> , 2010, 102, 325-339.	3.0	493
62	The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years. <i>Journal of Infectious Diseases</i> , 2009, 199, 926-935.	1.9	528
63	A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Sexually Active Women Aged 16-26 Years. <i>Journal of Infectious Diseases</i> , 2009, 199, 936-944.	0.7	272
64	Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. <i>Hum Vaccin</i> , 2009, 5, 696-704.	2.4	184
65	The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years. <i>Journal of Infectious Diseases</i> , 2009, 199, 936-944.	1.9	243
66	Genital herpes: Gynaecological aspects. <i>International Journal of Gynecology and Obstetrics</i> , 2009, 104, 162-166.	1.0	1
67	Guidelines for the management of herpes simplex virus in pregnancy. <i>International Journal of Gynecology and Obstetrics</i> , 2009, 104, 167-171.	1.0	18
68	Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine. <i>Journal of Infectious Diseases</i> , 2009, 199, 805-814.	1.9	436
69	Immunization in Pregnancy. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2009, 31, 1085-1092.	0.3	31
70	HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. <i>Vaccine</i> , 2008, 26, 6844-6851.	1.7	168
71	RETIRED: Immunization in Pregnancy. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2008, 30, 1149-1154.	0.3	12
72	Guidelines for the Management of Herpes Simplex Virus in Pregnancy. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2008, 30, 514-519.	0.3	35

#	ARTICLE	IF	CITATIONS
73	In Response. Journal of Obstetrics and Gynaecology Canada, 2008, 30, 768-769.	0.3	1
74	Missed Hormonal Contraceptives: New Recommendations. Journal of Obstetrics and Gynaecology Canada, 2008, 30, 1050-1062.	0.3	16
75	Directive clinique sur la prise en charge du virus de l'hépatite B pendant la grossesse. Journal of Obstetrics and Gynaecology Canada, 2008, 30, 520-526.	0.3	1
76	Genital Herpes: Gynaecological Aspects. Journal of Obstetrics and Gynaecology Canada, 2008, 30, 347-353.	0.3	7
77	Do you approve of spending \$300 million on HPV vaccination?: yes. Canadian Family Physician, 2008, 54, 174, 176, 178, 180.	0.1	2
78	Rebuttal: Do you approve of spending \$300 million on HPV vaccination? Yes. Canadian Family Physician, 2008, 54, 342, 344.	0.1	0
79	Noninferiority of Antibody Response to Human Papillomavirus Type 16 in Subjects Vaccinated with Monovalent and Quadrivalent L1 Virus-Like Particle Vaccines. Vaccine Journal, 2007, 14, 792-795.	3.2	35
80	RETIRED: Canadian Consensus Guidelines on Human Papillomavirus. Journal of Obstetrics and Gynaecology Canada, 2007, 29, S1.	0.3	18
81	Counselling. Journal of Obstetrics and Gynaecology Canada, 2007, 29, S55-S56.	0.3	1
82	Principes de tératologie humaine : Exposition aux médicaments aux produits chimiques et aux agents infectieux. Journal of Obstetrics and Gynaecology Canada, 2007, 29, 918-926.	0.3	1
83	Clinical Manifestations and Diagnosis of HPV-Related Disease. Journal of Obstetrics and Gynaecology Canada, 2007, 29, S11-S14.	0.3	0
84	Principles of Human Teratology: Drug Chemical and Infectious Exposure. Journal of Obstetrics and Gynaecology Canada, 2007, 29, 911-917.	0.3	25
85	Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet, The, 2007, 369, 1693-1702.	6.3	579
86	Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases. New England Journal of Medicine, 2007, 356, 1928-1943.	13.9	1,741
87	Human papillomavirus infection: Epidemiology and pathophysiology. Gynecologic Oncology, 2007, 107, S2-S5.	0.6	223
88	Chapter 25: Education, training, and communication for HPV vaccines. Vaccine, 2006, 24, S210-S218.	1.7	66
89	HIV Screening in Pregnancy. Journal of Obstetrics and Gynaecology Canada, 2006, 28, 1103-1107.	0.3	20
90	Dépistage du VIH au cours de la grossesse. Journal of Obstetrics and Gynaecology Canada, 2006, 28, 1108-1112.	0.3	0

#	ARTICLE	IF	CITATIONS
91	Neonatal Herpes Simplex Virus Infections in Canada: Results of a 3-Year National Prospective Study. <i>Pediatrics</i> , 2006, 117, 1955-1962.	1.0	132
92	Genital Herpes Simplex Virus Infection. <i>Clinical Obstetrics and Gynecology</i> , 2005, 48, 838-844.	0.6	12
93	The Resurgence of <i>Chlamydia trachomatis</i> . <i>Journal of Obstetrics and Gynaecology Canada</i> , 2004, 26, 552-559.	0.3	2
94	Hepatitis C Virus Is Related to Progressive Liver Disease in Human Immunodeficiency Virus-Positive Hemophiliacs and Should Be Treated as an Opportunistic Infection. <i>Journal of Infectious Diseases</i> , 1999, 179, 1254-1258.	1.9	203
95	Family Practitioners and Sexually Transmitted Diseases. <i>Canadian Journal of Infectious Diseases &amp; Medical Microbiology</i> , 1991, 2, 27-30.	0.3	1
96	Cognitief-gedragstherapeutische relatietherapie versus lidocaïne voor "provoked vulvodynie": een gerandomiseerde klinische trial. <i>Gezinstherapie Wereldwijd</i> , 0, , 1.	0.0	0